We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

4 hedge funds and large institutions have $4K invested in NRX Pharmaceuticals Warrant in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

83% less capital invested

Capital invested by funds: $24K → $4K (-$20K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.68K
2
UBS Group
UBS Group
Switzerland
+$91

Top Sellers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
YCM
1
Yakira Capital Management
Connecticut
$2K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$2K +$7.68K +15,678 New
Cambridge Investment Research Advisors
3
Cambridge Investment Research Advisors
Iowa
– -$9K -10,000 Closed
UBS Group
4
UBS Group
Switzerland
– +$91 +186 New

NRXPW Hedge Fund Activity: Q2 2022 in Review

4 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q2 2022, worth a combined $4K — down 83% from $24K a quarter earlier.

Fund positioning in NRXPW was balanced in Q2 2022: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $7.68K. The largest seller was Cambridge Investment Research Advisors, exiting entirely with an estimated $9K sold.

  • 4 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $4K of NRX Pharmaceuticals Warrant stock for Q2 2022, down 83% quarter-over-quarter.
  • 2 funds opened new NRX Pharmaceuticals Warrant positions in Q2 2022 and 2 closed out, a net change of 0 holders.
  • The largest NRX Pharmaceuticals Warrant buyer in Q2 2022 was Susquehanna International Group, an estimated $7.68K added.
  • The largest NRX Pharmaceuticals Warrant seller in Q2 2022 was Cambridge Investment Research Advisors, an estimated $9K sold.

Based on aggregated 13F filings for Q2 2022.